Related Experiment Video

Updated: Jun 26, 2026

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle
09:35

Development of a Hepatitis B Virus Reporter System to Monitor the Early Stages of the Replication Cycle

Published on: February 1, 2017

Development of novel treatments for hepatitis C

Daniel P Webster1, Paul Klenerman, Jane Collier

  • 1Department of Microbiology, John Radcliffe Hospital, Oxford, UK. danwebster@doctors.org.uk

The Lancet. Infectious Diseases
|January 31, 2009
PubMed

Insights

Hepatitis C virus (HCV) infection affects 170 million globally, causing liver disease. New research in HCV biology and animal models is crucial for developing effective treatments beyond current therapies.

Area of Science:

  • Hepatology
  • Virology
  • Infectious Diseases

Background:

  • Hepatitis C virus (HCV) infection is a significant global health concern, impacting 170 million individuals.
  • HCV is a primary cause of liver cirrhosis and hepatocellular carcinoma.
  • Current treatments (interferon alfa and ribavirin) have limited efficacy (around 50%) and necessitate improved options.

Purpose of the Study:

  • To review advancements in Hepatitis C virus (HCV) biology.
  • To highlight the role of cell culture and animal models in understanding HCV.
  • To discuss progress in developing targeted antiviral therapies for HCV.

Main Methods:

  • Review of scientific literature on HCV biology, cell culture, and animal models.
  • Analysis of research contributions to understanding HCV life-cycle and pathogenesis.
  • Examination of developments in HCV epidemiology, clinical manifestations, and diagnostics.

Main Results:

  • Progress in cell culture and animal models has significantly advanced HCV research.
  • Enhanced understanding of HCV life-cycle and pathogenesis is emerging.
  • Development of targeted antiviral treatments is progressing.

Conclusions:

  • Advances in HCV biology research are critical for overcoming treatment limitations.
  • Improved models and understanding are paving the way for novel therapies.
  • Further research is needed to address the global burden of Hepatitis C.

More Related Videos

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...